By Kimberly N. Alleyne
Stroudsburg, Pa., Aug. 29- Amnis Corp. announced Monday its initial closing of a $6 million series C financing round, bringing in more than $3 million in capital.
The company will use the proceeds to expand commercial operations and accelerate key clinical application and product development programs already in progress.
Participants included a consortium of a dozen new, private investors as well as Amnis' existing investors.
"This round of funding puts us in an excellent position to achieve profitability," said David Basiji, Amni president and chief executive officer, in a news release. "Our burn rate is modest, our people are energized, and our products are a true breakthrough for the life sciences and clinical diagnostics markets. With this money, we'll establish the ImageStream 100 product, develop our second-generation products, and demonstrate feasibility for multiple clinical applications."
Amnis Corp. is headquartered in Seattle and develops, manufactures and markets instrumentation for high speed imaging of cells in flow.
| Issuer: | Amnis Corp.
|
| Issue: | Product development financing
|
| Round: | C
|
| Amount: | $3 million (initial closing of $6 million round)
|
| Announcement date: | Aug. 29
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
